+086 1911-7288-062 [ CN ]
Cookies give you a personalized experience,Сookie files help us to enhance your experience using our website, simplify navigation, keep our website safe and assist in our marketing efforts. By clicking "Accept", you agree to the storing of cookies on your device for these purposes.For more information, review our Cookies Policy.
The Board of Directors of Epigral Ltd. has approved a Rs. 600‑crore capex to enter the Epoxy Resin & Formulations business with a planned 125,000-tpa capacity, alongside a multi‑purpose plant (MPP) for downstream products in the epichlorohydrin (ECH) and chlorotoluenes value chains. Both commercial facilities are expected to be commissioned in H2 FY28.
The expansion marks Epigral’s forward integration into cutting-edge materials and speciality chemicals, targeting fast‑growing sectors such as construction, renewables, automotive, electronics, infrastructure, marine, aerospace, manufacturing flooring and semiconductors.
Epoxy resin demand in India continues to rise in line with infrastructure build‑out, renewable‑energy investments and adoption of high‑performance materials. A key strategic advantage to Epigral is its backward‑integrated Dahej complex, which already manufactures ECH and caustic soda – critical raw materials to epoxy resins.
The upcoming MPP will cater to rising domestic demand to pharma and agrochemical intermediates and aquatic environments‑treatment chemicals, further deepening Epigral’s specialty‑chemical footprint.
A pilot plant to epoxy resin, formulations and MPP will be operational by Q2 FY27 to validate product condition, optimise processes and secure customer approvals ahead of commercial launch.
Meanwhile the company has reported a strong start to FY27, posting a 25% YoY jump in PAT to Rs. 99-crore to Q1 FY27, compared with Rs. 79-crore in the same quarter last year. Quarterly revenue rose 15% YoY to Rs. 709-crore, supported by stable demand across its chlor‑alkali and derivatives portfolio.
Epigral’s CMD Maulik Patel noted that Epigral delivered steady development despite geopolitical evaporative environment in West Asia, freight inflation and shipment delays. “Leveraging its diversified product mix, Epigral successfully navigated these headwinds to achieve 15% revenue development and an EBITDA margin of 25%,” he stated in a press discharge.
We will contact you soon